Literature DB >> 19760033

The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer.

Emmet McIntyre1, Edith Blackburn, Philip J Brown, Colin G Johnson, William J Gullick.   

Abstract

The levels of expression of the four receptors and eleven ligands composing the epidermal growth factor family were measured using immunohistochemical staining in one hundred cases of breast cancer. All of the family were expressed to some degree in some cases; however, individual cases showed a very wide range of expression of the family from essentially none to all the factors at high levels. The highest aggregate level of expression of a receptor was HER2 followed by HER1, then HER3, then HER4. The ligands (including two splice variants of the NRG1 and NRG2 genes) broadly fell into three groups, those with the highest aggregate expression were Epigen, Epiregulin, Neuregulin 1alpha, Neuregulin 2alpha, Neuregulin 2beta, Neuregulin 4 and TGFalpha, moderate expression was seen with EGF, Neuregulin 1beta and Neuregulin 3, and relatively low levels of expression were seen of HB-EGF, Betacellulin and Amphiregulin. Statistical analysis using Spearman's Rank Correlation showed a positive correlation of expression between each of the factors. Analysing the data using the Cox Proportional Hazards model showed that, in this dataset, the most powerful predictors of relapse free interval and overall survival were the combined measurement of only Epigen and Neuregulin 4.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19760033     DOI: 10.1007/s10549-009-0536-5

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  19 in total

Review 1.  Epiregulin: roles in normal physiology and cancer.

Authors:  David J Riese; Richard L Cullum
Journal:  Semin Cell Dev Biol       Date:  2014-03-12       Impact factor: 7.727

Review 2.  ErbB/EGF signaling and EMT in mammary development and breast cancer.

Authors:  Katharine M Hardy; Brian W Booth; Mary J C Hendrix; David S Salomon; Luigi Strizzi
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-04-06       Impact factor: 2.673

Review 3.  Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities.

Authors:  Xiaoxin Ren; Yixian Li; Christopher Nishimura; Xingxing Zang
Journal:  Genes Dis       Date:  2021-09-20

Review 4.  Structure and function of epigen, the last EGFR ligand.

Authors:  Marlon R Schneider; Yosef Yarden
Journal:  Semin Cell Dev Biol       Date:  2013-12-25       Impact factor: 7.727

5.  Expression of NRG1 and its receptors in human bladder cancer.

Authors:  J A Forster; A B Paul; P Harnden; M A Knowles
Journal:  Br J Cancer       Date:  2011-03-01       Impact factor: 7.640

6.  Comparative analysis of the human hepatic and adipose tissue transcriptomes during LPS-induced inflammation leads to the identification of differential biological pathways and candidate biomarkers.

Authors:  Ewa Szalowska; Martijn Dijkstra; Marieke G L Elferink; Desiree Weening; Marcel de Vries; Marcel Bruinenberg; Annemieke Hoek; Han Roelofsen; Geny M M Groothuis; Roel J Vonk
Journal:  BMC Med Genomics       Date:  2011-10-06       Impact factor: 3.063

7.  Interaction of tumor cells with the microenvironment.

Authors:  Hendrik Ungefroren; Susanne Sebens; Daniel Seidl; Hendrik Lehnert; Ralf Hass
Journal:  Cell Commun Signal       Date:  2011-09-13       Impact factor: 5.712

8.  Quantum dot-based quantitative immunofluorescence detection and spectrum analysis of epidermal growth factor receptor in breast cancer tissue arrays.

Authors:  Xue-Qin Yang; Chuang Chen; Chun-Wei Peng; Jin-Xuan Hou; Shao-Ping Liu; Chu-Bo Qi; Yi-Ping Gong; Xiao-Bo Zhu; Dai-Wen Pang; Yan Li
Journal:  Int J Nanomedicine       Date:  2011-10-11

9.  2D protrusion but not motility predicts growth factor-induced cancer cell migration in 3D collagen.

Authors:  Aaron S Meyer; Shannon K Hughes-Alford; Jennifer E Kay; Amalchi Castillo; Alan Wells; Frank B Gertler; Douglas A Lauffenburger
Journal:  J Cell Biol       Date:  2012-06-04       Impact factor: 10.539

10.  A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF.

Authors:  Shuji Sato; Andrew W Drake; Isamu Tsuji; Jinhong Fan
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.